PMID- 30232695
OWN - NLM
STAT- MEDLINE
DCOM- 20190711
LR  - 20190711
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 78
IP  - 14
DP  - 2018 Sep
TI  - Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
PG  - 1481-1488
LID - 10.1007/s40265-018-0969-4 [doi]
AB  - Intravenous elotuzumab (Empliciti), a monoclonal antibody targeting the 
      signalling lymphocytic activation molecule F7 (SLAMF7) glycoprotein, is approved 
      for use in combination with lenalidomide and dexamethasone for the treatment of 
      multiple myeloma in previously-treated adult patients. In the pivotal, 
      multinational, phase III ELOQUENT-2 trial in adults with relapsed and/or 
      refractory multiple myeloma, elotuzumab in combination with lenalidomide and 
      dexamethasone significantly prolonged median progression-free survival (PFS) and 
      increased overall response rate (ORR; co-primary endpoints) compared with 
      lenalidomide and dexamethasone alone. The clinical benefit of elotuzumab was 
      maintained over the longer term (</= 4 years' minimum follow-up); final overall 
      survival data are awaited. Health-related quality of life was not negatively 
      impacted by the addition of elotuzumab. Elotuzumab combination therapy had a 
      generally manageable tolerability profile and the most common adverse events 
      (AEs) of grade >/= 3 severity were haematological (e.g. lymphocytopenia, anaemia, 
      thrombocytopenia, neutropenia). Elotuzumab plus lenalidomide and dexamethasone 
      extends the treatment options available for the management of relapsed and/or 
      refractory multiple myeloma.
FAU - Lamb, Yvette N
AU  - Lamb YN
AD  - Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. 
      demail@springer.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 1351PE5UGS (elotuzumab)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - F0P408N6V4 (Lenalidomide)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/adverse effects/pharmacology/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse 
      effects/pharmacology/*therapeutic use
MH  - Clinical Trials, Phase III as Topic
MH  - Dexamethasone/administration & dosage
MH  - Humans
MH  - Lenalidomide/administration & dosage
MH  - Multiple Myeloma/*drug therapy
MH  - Programmed Cell Death 1 Receptor/immunology/metabolism
MH  - Progression-Free Survival
MH  - Quality of Life
MH  - Recurrence
MH  - Treatment Failure
EDAT- 2018/09/21 06:00
MHDA- 2019/07/12 06:00
CRDT- 2018/09/21 06:00
PHST- 2018/09/21 06:00 [pubmed]
PHST- 2019/07/12 06:00 [medline]
PHST- 2018/09/21 06:00 [entrez]
AID - 10.1007/s40265-018-0969-4 [pii]
AID - 10.1007/s40265-018-0969-4 [doi]
PST - ppublish
SO  - Drugs. 2018 Sep;78(14):1481-1488. doi: 10.1007/s40265-018-0969-4.